Article · AI translation
IT Home reported on November 17 that Isomorphic Labs, an Alphabet subsidiary developing drugs with AI and led by Nobel laureate Demis Hassabis, announced today local time that it had completed a Series C funding round totaling $5 billion (IT Home note: approximately 33.396 billion yuan at the current exchange rate).
The round was co-led by Greenoaks and Sequoia Capital, with new investors including a16z (Andreessen Horowitz) joining. Alphabet continued to invest substantial funds, while existing investors including Thrive Capital, MGX, GV, CapitalG, Temasek, and the UK Sovereign AI Fund also participated.
Isomorphic Labs plans to use the funds to continue developing foundational simulation models, expand the scale of its internal and partnered drug candidate programs, and build global AI-driven bioengineering infrastructure.